FY22-DBH- Naloxone HCL 4MG Nasal Spray

The District of Columbia is seeking to procure Naloxone HCL 4MG Nasal Spray through a competitive procurement process for fiscal year 2022, specifically targeting the Department of Behavioral Health (DBH). The contract opportunity, identified by the unique ID 66c855fbcac5fc795d0f5e5a, is soliciting proposals for the acquisition of this critical overdose reversal medication. The procurement is designed to secure a reliable supply of nasal spray naloxone, which is essential for emergency response and harm reduction efforts. Proposals must be submitted by April 8, 2022, providing vendors approximately one month from the posting date of March 10, 2022, to prepare and respond to the solicitation. While specific evaluation criteria are not detailed in the provided information, typical municipal procurements assess vendor qualifications, pricing, delivery capabilities, product specifications, and compliance with local purchasing regulations.

The contract opportunity does not explicitly specify set-aside designations or restrictions on respondent types, though District of Columbia procurement typically encourages participation from local, small, and disadvantaged business enterprises. No incumbent vendors or specific integration requirements are mentioned in the available information. The procurement appears focused on acquiring a standard medical supply with likely volume-based pricing, though precise budget ranges are not specified. Vendors interested in responding should carefully review the full solicitation documents to understand the exact specifications for the Naloxone HCL 4MG Nasal Spray, potential delivery schedules, packaging requirements, and any technical specifications that might influence proposal preparation. Prospective bidders should also ensure they meet any required qualifications for supplying pharmaceutical products to a municipal behavioral health department.